Optimal combination therapy for metastatic hormone-sensitive prostate cancer: new evidence, challenges and unanswered questions.
Journal
Current opinion in urology
ISSN: 1473-6586
Titre abrégé: Curr Opin Urol
Pays: United States
ID NLM: 9200621
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
pubmed:
21
8
2023
medline:
21
8
2023
entrez:
21
8
2023
Statut:
ppublish
Résumé
To evaluate the evidence supporting treatment intensification in mHSPC, with a focus on possible indications for treatment in each clinical setting. There is a growing armamentarium of treatment options for patients with metastatic hormone-sensitive prostate cancer (mHSPC). These include combinations of treatments such as androgen deprivation therapy (ADT), docetaxel, and new antiandrogenic therapies. Treatment intensification with chemotherapy or newer hormonal agents may improve patient's oncologic outcomes, but it can also come with additional toxicities and costs. Therefore, we need to take into account individual patient factors and preferences when deciding on the optimal combination therapy. Additionally, ongoing research is needed to identify biomarkers and new image techniques that can predict response to treatment and identify the best candidate for each treatment. Challenges and unanswered questions regarding treatment intensification and de-intensification are still present. Further studies are still needed to identify which patients would benefit most from this approach to improve quality of life without compromising overall survival outcomes.
Identifiants
pubmed: 37603006
doi: 10.1097/MOU.0000000000001124
pii: 00042307-990000000-00107
pmc: PMC10552828
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
445-451Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Eur Urol Focus. 2023 Jul;9(4):637-641
pubmed: 36697321
Prostate Cancer Prostatic Dis. 2023 Mar;26(1):170-179
pubmed: 36284192
World J Urol. 2023 Jan;41(1):67-75
pubmed: 36520204
Eur Urol Oncol. 2022 Oct;5(5):494-502
pubmed: 35811293
JAMA Oncol. 2020 May 1;6(5):650-659
pubmed: 32215577
Eur Urol. 2020 Apr;77(4):508-547
pubmed: 32001144
Lancet Oncol. 2019 May;20(5):686-700
pubmed: 30987939
N Engl J Med. 2022 Mar 24;386(12):1132-1142
pubmed: 35179323
Eur Urol. 2021 Feb;79(2):243-262
pubmed: 33172724
JAMA Oncol. 2023 May 1;9(5):635-645
pubmed: 36862387
J Clin Oncol. 2018 Feb 10;36(5):446-453
pubmed: 29240541
Eur Urol Oncol. 2022 Dec;5(6):605-616
pubmed: 35599144
Lancet. 2022 Apr 30;399(10336):1695-1707
pubmed: 35405085
Eur Urol Focus. 2023 Apr 11;:
pubmed: 37055323
JAMA Oncol. 2023 Jun 1;9(6):825-834
pubmed: 37022702
Eur Urol. 2023 Jun;83(6):481-483
pubmed: 36774222
Lancet Oncol. 2023 Apr;24(4):323-334
pubmed: 36990608
Eur Urol. 2019 Jul;76(1):115-124
pubmed: 30826218
Lancet. 2018 Dec 1;392(10162):2353-2366
pubmed: 30355464
Eur Urol. 2019 Mar;75(3):410-418
pubmed: 30266309
J Clin Oncol. 2022 Oct 10;40(29):3377-3382
pubmed: 36001857
J Clin Oncol. 2023 Jul 10;41(20):3595-3607
pubmed: 36795843
Lancet Oncol. 2023 Mar;24(3):e121-e132
pubmed: 36858728
Cancer Med. 2021 Dec;10(23):8570-8580
pubmed: 34725947
PLoS Med. 2022 Jun 7;19(6):e1003998
pubmed: 35671327
Lancet Oncol. 2023 Jul;24(7):783-797
pubmed: 37414011
Cancer Treat Rev. 2022 Nov;110:102441
pubmed: 35939976